{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:04:58Z","timestamp":1787868298601,"version":"build-2784847793"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.bmc.2023.117518","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T02:51:03Z","timestamp":1699325463000},"page":"117518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["New aryl-\/heteroarylpiperazine derivatives of 1,7-dimethyl-8,9-diphenyl-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5,10-trione: Synthesis and preliminary studies of biological activities"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1174-2208","authenticated-orcid":false,"given":"Mariola","family":"Napi\u00f3rkowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmara","family":"Kurpios-Piec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Kiernozek-Kali\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Le\u015bniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Klawikowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Bujalska-Zadro\u017cny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2023.117518_b0005","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/84683","article-title":"Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase","volume":"7","author":"Vigneri","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2023.117518_b0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/pr.55.3.4","article-title":"Specific targeted therapy of chronic myelogenous leukemia with imatinib","volume":"55","author":"Deininger","year":"2003","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bmc.2023.117518_b0015","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bmc.2023.117518_b0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.critrevonc.2005.06.007","article-title":"Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)","volume":"57","author":"Walz","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bmc.2023.117518_b0025","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1021\/bi100200c","article-title":"Incorporation of gemcitabine and cytarabine into DNA by DNA polymerase beta and ligase III\/XRCC1","volume":"49","author":"Prakasha Gowda","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2023.117518_b0030","first-page":"641","article-title":"Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding","volume":"32","author":"Bloemink","year":"1996","journal-title":"Met Ions Biol Syst"},{"key":"10.1016\/j.bmc.2023.117518_b0035","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2023.117518_b0040","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djj069","article-title":"BAY 43\u20139006 inhibition of oncogenic RET mutants","volume":"98","author":"Carlomagno","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bmc.2023.117518_b0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2023.117518_b0050","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1470-2045(11)70002-X","article-title":"Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies","volume":"12","author":"Mitchell","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2023.117518_b0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/TPSY.TPSY_3_19","article-title":"Antidepressant therapy in patients with cancer: a clinical review","volume":"33","author":"Shen-Chieh","year":"2019","journal-title":"Taiwan J Psychiat"},{"key":"10.1016\/j.bmc.2023.117518_b0060","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-15-2242","article-title":"Lenalidomide, thalidomide, and pomalidomide reactivate the Epstein-Barr virus lytic cycle through phosphoinositide 3-kinase signaling and ikaros expression","volume":"22","author":"Jones","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2023.117518_b0065","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.1989.7.9.1351","article-title":"Phase I clinical investigation of amonafide","volume":"7","author":"Saez","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2023.117518_b0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF00877243","article-title":"Phase I study of mitonafide in solid tumors","volume":"10","author":"Llombart","year":"1992","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.bmc.2023.117518_b0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1756-9966-29-175","article-title":"6-Nitro-2-(3-hydroxypropyl)-1H-benz[de]isoquinoline-1,3-dione, a potent antitumor agent, induces cell cycle arrest and apoptosis","volume":"29","author":"Mukherjee","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.bmc.2023.117518_b0080","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1021\/jm100025u","article-title":"A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis","volume":"53","author":"Chen","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117518_b0085","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.3390\/molecules19066911","article-title":"Synthesis of novel lipophilic N-substituted norcantharimide derivatives and evaluation of their anticancer activities","volume":"19","author":"Wu","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2023.117518_b0090","first-page":"827","article-title":"Hybrids of oleanolic acid with norbornene-2,3-dicarboximide-N-carboxylic acids as potential anticancer agents","volume":"74","author":"Bednarczyk-Cwynar","year":"2017","journal-title":"Acta Pol Pharm"},{"key":"10.1016\/j.bmc.2023.117518_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174082","article-title":"Multiple myeloma therapy: emerging trends and challenges","volume":"14","author":"Dima","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2023.117518_b0100","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1016\/j.bmc.2008.02.005","article-title":"Synthesis and anti-cancer activity of benzothiazole containing phthalimide on human carcinoma cell lines","volume":"16","author":"Kok","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2023.117518_b0105","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ejmech.2015.04.041","article-title":"Design, synthesis and structure-activity relationship of phthalimides endowed with dual antiproliferative and immunomodulatory activities","volume":"96","author":"Cardoso","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2023.117518_b0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0753-3322(96)82631-X","article-title":"The cytotoxicity of N-Pyridinyl and N-quinolinyl substituted derivatives of phthalimide and succinimide","volume":"49","author":"Hall","year":"1995","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2023.117518_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105677","article-title":"Recent developments on 1,8-Naphthalimide moiety as potential target for anticancer agents","volume":"121","author":"Tandon","year":"2022","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2023.117518_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112967","article-title":"An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: a review","volume":"210","author":"Girase","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2023.117518_b0125","first-page":"4244","article-title":"Synthesis, chemical characterization and evaluation of antimicrobial activity of some novel quinoxalines","volume":"13","author":"Birajdar","year":"2022","journal-title":"Int J Pharm Sci Res"},{"key":"10.1016\/j.bmc.2023.117518_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3906\/kim-1806-7","article-title":"An insight into therapeutic potential of piperazine-based anticancer agents","volume":"43","author":"Walayat","year":"2019","journal-title":"Turk J Chem"},{"key":"10.1016\/j.bmc.2023.117518_b0135","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2174\/1871520616666160223114318","article-title":"New, substituted derivatives of dicarboximides and their cytotoxic properties","volume":"16","author":"Kuran","year":"2016","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.bmc.2023.117518_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/biom9090446","article-title":"New thalidomide-resembling dicarboximides target ABC50 protein and show antileukemic and immunomodulatory activities","volume":"9","author":"Cieslak","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.bmc.2023.117518_b0145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094318","article-title":"New succinimides with potent anticancer activity: synthesis, activation of stress signaling pathways and characterization of apoptosis in leukemia and cervical cancer cells","volume":"22","author":"Cieslak","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2023.117518_b0150","first-page":"459","article-title":"Proapoptotic activity of heterocyclic compounds containing succinimide moiety in the promyelocytic leukemia cell line HL-60","volume":"70","author":"Kuran","year":"2013","journal-title":"Acta Pol Pharm"},{"key":"10.1016\/j.bmc.2023.117518_b0155","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/11080615","article-title":"Synthesis of conformationally constrained aryl- or heteroarylpiperazinyl derivatives of selected imides as 5-HT1A receptor ligands","volume":"11","author":"Kossakowski","year":"2006","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2023.117518_b0160","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2174\/0929867013372599","article-title":"Serotonin receptor and transporter ligands - current status","volume":"8","author":"Oh","year":"2001","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2023.117518_b0165","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/90300170","article-title":"New imide 5-HT1A receptor ligands - modification of terminal fragment geometry","volume":"9","author":"Bojarski","year":"2004","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2023.117518_b0170","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1021\/jm991045h","article-title":"On the bioactive conformation of NAN-190 (1) and MP3022 (2), 5-HT(1A) receptor antagonists","volume":"42","author":"Paluchowska","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117518_b0175","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1021\/jm960416g","article-title":"Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxyphenyl)piperazin-1-yl]methyl]-1, 3-dioxoperhydroimidazo[1,5-alpha]pyridine: a selective 5-HT1A receptor agonist","volume":"39","author":"Lopez-Rodriguez","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117518_b0180","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.bmc.2005.09.060","article-title":"Structure-intrinsic activity relationship studies in the group of 1-imido\/amido substituted 4-(4-arylpiperazin-1-yl)cyclohexane derivatives; new, potent 5-HT1A receptor agents with anxiolytic- like activity","volume":"14","author":"Bojarski","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2023.117518_b0185","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2174\/156802606778522186","article-title":"Pharmacophore models for metabotropic 5-HT receptor ligands","volume":"6","author":"Bojarski","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2023.117518_b0190","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nrc1736","article-title":"Promoting apoptosis as a strategy for cancer drug discovery","volume":"5","author":"Fesik","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2023.117518_b0195","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/cdd.2009.180","article-title":"Neuronal caspase-3 signaling: not only cell death","volume":"17","author":"D'Amelio","year":"2010","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.bmc.2023.117518_b0200","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau9433","article-title":"Efficient apoptosis requires feedback amplification of upstream apoptotic signals by effector caspase-3 or -7","volume":"5","author":"McComb","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.bmc.2023.117518_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153641","article-title":"Novel dicarboximide BK124.1 breaks multidrug resistance and shows anticancer efficacy in chronic myeloid leukemia preclinical models and patients' CD34(+)\/CD38(-) leukemia stem cells","volume":"14","author":"Stukan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2023.117518_b0210","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2023.117518_b0215","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jgeb.2014.03.003","article-title":"Thalidomide dithiocarbamate and dithioate derivatives induce apoptosis through inhibition of histone deacetylases and induction of caspases","volume":"12","author":"Zahran","year":"2014","journal-title":"J Genet Eng Biotechnol"},{"key":"10.1016\/j.bmc.2023.117518_b0220","first-page":"163","article-title":"Novel tubulin-polymerization inhibitor derived from thalidomide directly induces apoptosis in human multiple myeloma cells: possible anti-myeloma mechanism of thalidomide","volume":"21","author":"Iguchi","year":"2008","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.bmc.2023.117518_b0225","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.mce.2011.05.033","article-title":"Interleukin-6: a multifunctional targetable cytokine in human prostate cancer","volume":"360","author":"Culig","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.bmc.2023.117518_b0230","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin Immunol"},{"key":"10.1016\/j.bmc.2023.117518_b0235","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2004.07.020","article-title":"TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling","volume":"21","author":"Becker","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.bmc.2023.117518_b0240","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","article-title":"Stat3\/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer","volume":"19","author":"Lesina","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2023.117518_b0245","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","article-title":"IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer","volume":"15","author":"Grivennikov","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2023.117518_b0250","first-page":"543","article-title":"Novel 4-alkyl-1-arylpiperazines and 1,2,3,4-tetrahydroisoquinolines containing diphenylmethylamino or diphenylmethoxy fragment with differentiated 5-HT1A\/5-HT2A\/D2 receptor activity","volume":"55","author":"Paluchowska","year":"2003","journal-title":"Pol J Pharmacol"},{"key":"10.1016\/j.bmc.2023.117518_b0255","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1016\/j.bmcl.2010.02.106","article-title":"New 5-HT(1A) receptor ligands containing a N'-cyanoisonicotinamidine nucleus: synthesis and in vitro pharmacological evaluation","volume":"20","author":"Fiorino","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2023.117518_b0260","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/0024-3205(90)90097-B","article-title":"Mixed agonist\/antagonist properties of NAN-190 at 5-HT1A receptors: behavioural and in vivo brain microdialysis studies","volume":"46","author":"Hjorth","year":"1990","journal-title":"Life Sci"},{"key":"10.1016\/j.bmc.2023.117518_b0265","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4155\/fmc.13.158","article-title":"Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?","volume":"6","author":"Zajdel","year":"2014","journal-title":"Fut Med Chem"},{"key":"10.1016\/j.bmc.2023.117518_b0270","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27196492","article-title":"Synthesis, docking studies and pharmacological evaluation of serotoninergic ligands containing a 5-norbornene-2-carboxamide nucleus","volume":"27","author":"Sparaco","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2023.117518_b0275","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-25761-2_2","article-title":"Role of dopamine D(2) receptors for antipsychotic activity","author":"Ginovart","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.bmc.2023.117518_b0280","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00210-019-01620-7","article-title":"New arylpiperazine derivatives with antidepressant-like activity containing isonicotinic and picolinic nuclei: evidence for serotonergic system involvement","volume":"392","author":"Kedzierska","year":"2019","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bmc.2023.117518_b0285","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1096\/fasebj.2.9.2836252","article-title":"Buspirone, a new approach to the treatment of anxiety","volume":"2","author":"Taylor","year":"1988","journal-title":"FASEB J"},{"key":"10.1016\/j.bmc.2023.117518_b0290","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-81077-y","article-title":"Histamine H1 receptor antagonists selectively kill cisplatin-resistant human cancer cells","volume":"11","author":"Matsumoto","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2023.117518_b0295","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/bph.14535","article-title":"Histamine receptors and cancer pharmacology: an update","volume":"177","author":"Massari","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2023.117518_b0300","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2567.2012.03565.x","article-title":"Histamine reduces susceptibility to natural killer cells via down-regulation of NKG2D ligands on human monocytic leukaemia THP-1 cells","volume":"136","author":"Nagai","year":"2012","journal-title":"Immunology"},{"key":"10.1016\/j.bmc.2023.117518_b0305","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1016\/j.bmc.2017.09.018","article-title":"New 5-HT(1A), 5HT(2A) and 5HT(2C) receptor ligands containing a picolinic nucleus: synthesis, in vitro and in vivo pharmacological evaluation","volume":"25","author":"Fiorino","year":"2017","journal-title":"Bioorg Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623003668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623003668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:24:09Z","timestamp":1760837049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089623003668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":61,"alternative-id":["S0968089623003668"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117518","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New aryl-\/heteroarylpiperazine derivatives of 1,7-dimethyl-8,9-diphenyl-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5,10-trione: Synthesis and preliminary studies of biological activities","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117518"}}